Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. BioNumerik is a private company which commenced operations in May 1992, was incorporated in Delaware in October
1992 and then reincorporated in Texas in July 1995. The company's pharmaceutical research teams are focused on
developing promising new classes of drugs for the treatment of cancer.
BioNumerik is a leader in a new area called “mechanism-based” drug discovery, which employs multi-disciplinary
science, including chemistry, biology and quantum physics, integrated with high performance computational
technologies, to identify, simulate and better understand the mechanisms by which drugs and their targets function. The
company's integrated approach aims to streamline drug development by selecting and optimising promising drugs or
compounds earlier in the discovery process, reducing the time and expense involved in laboratory testing.